Details

Access to disease-modifying therapies (DMTs) for Multiple Sclerosis represents a critical healthcare equity challenge in the UAE, where geographic dispersion, socioeconomic variations, and healthcare infrastructure differences create significant barriers to optimal patient care. This policy dialogue, organized by the Mohammed bin Rashid School of Government (MBRSG) in collaboration with the Dubai Health Authority and key healthcare stakeholders, examined how the UAE can systematically address disparities in DMT access across all seven emirates.
The dialogue brought together neurologists, healthcare administrators, insurance representatives, patient advocates, and policy makers to explore the multifaceted nature of MS care delivery, current implementation gaps, and strategic opportunities for improvement. Participants emphasized the need for a comprehensive approach that integrates geographic accessibility, socioeconomic considerations, insurance coverage optimization, and cross-emirate coordination.
Key findings indicate that, while the UAE has made significant investments in specialized neurological care, substantial disparities remain in access to DMT between urban centers, such as Dubai and Abu Dhabi, and more remote areas in the Northern Emirates. Insurance coverage inconsistencies, limited specialist availability outside major cities, and transportation barriers compound these challenges. The dialogue concluded with a consensus that transforming DMT accessibility requires coordinated policy intervention, enhanced infrastructure development, and innovative service delivery models supported by robust data analytics and cross-emirate collaboration.